Introduction
============

Nuclear DNA is wrapped around histone octamers consisting of histone H3, H4, H2A and H2B, which form the nucleosome, considered to be the fundamental unit of chromatin \[[@b1]\]. A primary role of chromatin is to control various cellular processes by manipulation of its architecture. Mechanisms that regulate chromatin structure, commonly known as epigenetic alterations, include histone post-translational modifications occurring by acetylation, methylation, phosphorylation, ubiquitination, sumoylation and ADP-ribosylation \[[@b2]\]. These reversible modifications are the basis of the \'histone code\' that controls gene activity, resulting in specific cellular phenotypes.

Changes in histone acetylation and methylation affect cardiac development and cause major cardiac pathologies (reviewed in \[[@b3],[@b4]\]). However, the role of other modifications, such as H3 phosphorylation, remains poorly understood. In organs with high proliferative capacities, H3 phosphorylation at serine 10 (p-H3 S10) is associated with mitosis, chromosome condensation and transcriptional activation \[[@b5]--[@b10]\]. In cardiac muscle, p-H3 S10 is detected in proliferating cardiomyocytes during fetal life, during the first week of post-natal life and in cardiomyocytes of young adults \[[@b11],[@b12]\]. After pathological insult, H3 phosphorylation increases in the adult heart \[[@b13],[@b14]\]. However, the role of this modification and the physiological H3 kinases involved have been overlooked.

Heart failure remains a major cause of mortality worldwide \[[@b15]\]. Heart failure is often preceded by a phase of cardiac hypertrophy associated with re-activation of fetal cardiac genes, such as atrial natriuretic peptide (ANP) and *β*-myosin heavy chain (*β*-MHC) \[[@b16],[@b17]\]. Mechanisms controlling this switch include the ATP-dependent chromatin remodeller Brg1, which recruits the histone deacetylase HDAC4 and PARP1 \[[@b18]\]. CaMKII*δ*, a critical mediator of a variety of cardiovascular disorders \[[@b19]--[@b22]\], regulates cardiac hypertrophy by interfering with the activity of HDACs \[[@b23],[@b24]\]. We recently reported that in isolated cardiomyocytes, CaMKII*δ* not only signals to HDAC4 but to chromatin itself \[[@b25]\]. In the present study, we address the *in vivo* function of CaMKII*δ* in H3 phosphorylation and the underlying mechanism. Using mice with global deletion of CaMKII*δ* \[[@b20]\] and samples from patients in end-stage heart failure, we show that CaMKII*δ* controls H3 phosphorylation in the adult heart in response to pressure overload. One underlying mechanism involves binding of the chaperone protein 14--3--3 to phosphorylated H3, which allows transcription elongation of hypertrophy genes by RNA polymerase II (RNAPII). These results reveal a novel function of CaMKII*δ* in regulating H3 phosphorylation in response to haemodynamic stress, and suggest a new epigenetic mechanism for the control of growth mechanisms in the diseased heart.

Materials and methods
=====================

Detailed methods are provided in Supplementary materials and methods (see supplementary material).

Human tissue dissection, histology and immunofluorescence
---------------------------------------------------------

All human and animal studies were approved by the institutional review board at King Faisal Specialist Hospital and Research Centre (KFSHRC) and at San Diego State University. Written informed consent was received by each participant prior to inclusion in the research study. Human hearts were obtained from KFSHRC from patients with end-stage heart failure and from donors who died of accidental death (control hearts). Samples from the same region of the left ventricle were dissected from the normal and cardiomyopathic hearts. Frozen and paraffin-embedded cardiac sections were prepared for histology in the Pathology Department of KFSHRC. For indirect immunofluorescence, frozen human heart sections were incubated with the indicated antibodies for 2 h at room temperature and, after washing, sections were incubated with secondary antibodies. Mouse heart sections were subjected to sequential double immunostaining when indicated, using GATA-4 and p-H3S10 antibodies, as described in Supplementary materials and methods (see supplementary material). Primary neonatal rat cardiomyocytes were incubated with primary and secondary antibodies, using standard methods and as reported previously \[[@b25]\].

Mice, thoracic aortic constriction and echocardiography
-------------------------------------------------------

CaMKII*δ* knockout mice (CaMKII*δ*-KO) were obtained from Dr Eric Olson \[[@b20]\]. Littermate 8--12 week-old male mice were subjected to thoracic aortic constriction (TAC) or sham operation, as described previously \[[@b20]\]. Left ventricular dimensions and cardiac function were measured at baseline and after sham operation or TAC surgery in mice sedated with 1--2% isofluorane, using a Vivid E9 high-resolution ultrasound system (GE).

Chromatin immunoprecipitation (ChIP) and qPCR
---------------------------------------------

ChIP and quatitative PCR (qPCR) assays were performed from primary neonatal rat cardiomyocytes and from mouse and human heart tissue, as described \[[@b25]\], with some modifications. Briefly, ChIP was performed with the indicated antibodies from approximately 1 × 10^6^ cells or 6 mg tissue after chromatin had been sheared to an average length of 600 bp. The immunoprecipitated DNA was analysed by qPCR with primers specific for the promoter regions of *ANP*, *β-MHC*, *GATA-4*, *GAPDH* and *actin*.

*In vitro* transcription
------------------------

*In vitro* transcription and gel shift assays were performed as described previously \[[@b25]\]. In summary, wild-type or mutant H3 S10A were reconstituted as octamers with the other core histones and were incubated with DNA templates carrying Mef2-responsive elements, CaMKII*δ*B, 14--3--3 and HeLa nuclear extracts, in the presence of *γ*^32^P-ATP. Transcription was measured by the formation of RNA corresponding to the transcribed Mef2.

Transfection of cardiomyocytes
------------------------------

Mutant H3 S10A was produced using the GENEART site-directed mutagenesis system (Invitrogen), as described previously \[[@b25]\]. Primary neonatal rat cardiomyocytes isolated using the Worthington Neonatal CardioMyocytes System (Worthington, USA) were co-transfected with a GFP-tagged plasmid and siControl (siCt) or siRNA against 14--3--3 (si14--3--3) from Dharmacon (Thermo Scientific, USA) using lipofectamine (Invitrogen). 24 h post-transfection, total cell lysates were prepared and analysed by western blotting or immunofluorescence.

Statistical analysis
--------------------

Data are presented as mean ± standard deviation (SD) or standard error of the mean (SEM). Differences between groups were calculated by unpaired two-tailed Student\'s *t*-test; *p* \< 0.05 was considered significant.

Results
=======

Increased H3 phosphorylation in human failing hearts
----------------------------------------------------

To assess H3 phosphorylation in the adult heart, we obtained samples from the left ventricle of control donor hearts and of patients in end-stage heart failure at the time of cardiac transplantation. Echocardiographic data showed cardiac dilatation and severely compromised cardiac function in patients with end-stage heart failure, with ejection fraction and fractional shortening averaging 16% and 9%, respectively (see supplementary material, [Table S1](#sd1){ref-type="supplementary-material"}, [Figure S1A](#sd1){ref-type="supplementary-material"}). Trichrome staining confirmed significant fibrosis in human failing hearts, whereas the hearts of normal individuals displayed almost no signs of pathology (see supplementary material, [Figure S1B](#sd1){ref-type="supplementary-material"}). Immunoblot analysis revealed a strong increase in p-H3 S10 in dilated human hearts compared to control hearts, which was paralleled by increased expression of CaMKII*δ* ([Figure 1](#fig01){ref-type="fig"}A, B). As expected, heart failure markers, such as ANP and *β*-MHC, were up-regulated in failing hearts, whereas total H3 and GAPDH expression remained unchanged ([Figure 1](#fig01){ref-type="fig"}A, B). In addition, expression of GATA-4 and c-Myc, which are known to drive cardiac hypertrophy \[[@b26]\], were increased in human failing hearts ([Figure 1](#fig01){ref-type="fig"}A--J). Enhanced p-H3 S10 was also detected by indirect immunofluorescence (see supplementary material, [Figure S2](#sd1){ref-type="supplementary-material"}). Together, these results show a robust increase in p-H3S10 in end-stage human heart failure, associated with increased expression of hypertrophic gene markers as well as transcriptional activators driving cardiac hypertrophy.

![Increased p-H3 S10 in end-stage human heart failure and in rodent heart after pressure overload. (A) Immunoblot of control donor hearts (*n =* 4) and hearts of patients with end-stage heart failure (*n =* 4), showing increased p-H3 S10 in dilated human hearts. Consistent with the dilation phenotype, expression of CaMKII*δ*, ANP, *β*-MHC, c-Myc and GATA-4 increased in failing hearts, whereas GAPDH and total H3 expression remained similar. (B) Quantitative analysis of (A); results are corrected for GAPDH and expressed as average ± SD; Student\'s *t*-test values are indicated. (C) Representative immunoblots, showing a progressive increase in p-H3 S10 after 10 days and 3 weeks of TAC in CaMKII*δ*-WT hearts but not in CaMKII*δ*-KO hearts. The hypertrophy marker proteins ANP, *β*-MHC c-Myc, GATA-4 and Mef2 are induced to different degrees in CaMKII*δ*-WT mice subjected to TAC, but not in CaMKII*δ*-KO mice after TAC. (D--J) Quantitative analysis of (C), performed in CaMKII*δ*-WT and CaMKII*δ*-KO mice after sham operation (*n =* 3) or TAC (*n =* 3). Values indicate expression of the indicated proteins ± SD, corrected for GAPDH. *p* values from Student\'s *t*-test are indicated](path0235-0606-f1){#fig01}

Next, we assessed H3--CaMKII*δ* interaction in the diseased human myocardium by immunoprecipitation. Binding of CaMKII*δ* to p-H3 S10 was detected in the human myocardium, whereas control IgG gave a lower background signal (see supplementary material, [Figure S3](#sd1){ref-type="supplementary-material"}). Thus, specific interaction between CaMKII*δ* and p-H3 S10 occurs in the human heart.

Lack of H3 hyperphosphorylation in CaMKII*δ* knockout mice after pressure overload
----------------------------------------------------------------------------------

To begin to investigate whether CaMKII*δ* regulates H3 phosphorylation *in vivo*, we measured global p-H3 S10 in mice lacking CaMKII*δ* (CaMKII*δ*-KO), which are resistant to pressure overload hypertrophy \[[@b20]\]. Western blot analysis showed increased p-H3 S10 after 10 days of TAC and a further increase 3 weeks post-TAC. Strikingly, p-H3 S10 remained low 10 days and 3 weeks post-TAC in CaMKII*δ*-KO mice ([Figure 1](#fig01){ref-type="fig"}C, E). In agreement with their published phenotypes \[[@b20]\], CaMKII*δ*-KO mice were protected against pressure overload hypertrophy and pathological cardiac remodelling, as shown by a significant decrease in the heart weight:body weight ratio, interventriculum thickness and reduced fibrosis compared to wild-type mice subjected to TAC (see supplementary material, [Figure S4](#sd1){ref-type="supplementary-material"}). Consistent with these changes, pressure overload increased the expression of ANP, *β*-MHC, c-Myc, GATA-4 and Mef2 in wild-type but not CaMKII*δ*-KO mice ([Figure 1](#fig01){ref-type="fig"}C--J). These results suggest that CaMKII*δ* regulates H3 phosphorylation in response to pressure overload.

Increased p-H3 S10 in ventricular myocytes and non-cardiac cells after pressure overload hypertrophy
----------------------------------------------------------------------------------------------------

P-H3 S10 is a mitotic marker commonly used to assess cellular proliferation \[[@b5],[@b27]\]. Since CaMKII*δ* is a critical regulator of cardiac hypertrophy \[[@b20]\], the observation that p-H3 S10 increases in response to pressure overload in wild-type but not CaMKII*δ*-KO mice suggests that p-H3 S10 may regulate not only cellular proliferation but also cellular hypertrophy. To test this hypothesis, we assessed p-H3 S10 in ventricular myocytes and in non-cardiac cells in heart sections of control donor hearts and failing human hearts. Double immunofluorescence using p-H3 S10 and *α*-actinin antibodies showed almost no p-H3 S10 signal in control hearts. In contrast, strong p-H3 S10 was detected in both ventricular myocytes and non-myocytes in human dilated hearts ([Figure 2](#fig02){ref-type="fig"}A). Quantitative analysis revealed \< 5% of p-H3 S10-positive cells in control hearts, with about half of the cells being myocytes and the other half being non-cardiac cells. In contrast, 85% of the cells stained positive for p-H3 S10 in failing human hearts. Among these, 27% were ventricular myocytes and 73% were non-myocyte cells ([Figure 2](#fig02){ref-type="fig"}B). Thus, H3 phosphorylation increases in both ventricular myocytes and non-cardiac cells in human failing hearts. To establish the functional link between H3 S10 phosphorylation and cardiac hypertrophy development, we transfected primary neonatal cardiomyocytes with wild-type-H3 or mutant H3S10A expression vectors and measured the effect on cell size. Double immunofluoroscence with *α*-actinin was performed to distinguish myocytes from non-cardiac cells, and revealed a significant reduction of myocyte surface area in cells expressing mutant H3 S10A compared to cells transfected with H3 (see supplementary material, [Figure S5](#sd1){ref-type="supplementary-material"}). These data indicate that H3 S10 phosphorylation plays a role in cellular hypertrophy development.

![Increased p-H3 S10 in human and rodent ventricular myocytes after pressure overload hypertrophy. (A) Double immunostaining was performed with p-H3 S10 (red) and *α*-actinin (green) antibody to visualize p-H3 S10 signals in ventricular myocytes, by fluorescence microscopy using a Nikon Eclipse Ti-E microscope with a × 20 or × 40 objective. (B) Quantitative analysis performed in 20 fields selected randomly, showing that ∼30% of ventricular myocytes are positive for p-H3 S10 in dilated human hearts, whereas only ∼8% of myocytes are positive for p-H3 S10 in normal human hearts. (C) Reduced p-H3 S10 in ventricular myocytes of CaMKII*δ*-KO mice subjected to TAC compared to wild-type mice subjected to 3 weeks of TAC. (D) Quantitative analysis of (C), performed in 20 fields selected randomly](path0235-0606-f2){#fig02}

Next, we investigated whether H3 phosphorylation is an early event in pathological cardiac remodelling. Sequential staining with GATA-4 and p-H3 antibodies revealed no detectable p-H3 S10 in sham-operated hearts, whereas approximately 30% of p-H3 S10 signal was detected in ventricular myocytes at 7 days, 4 weeks and 10 weeks post-TAC (see supplementary material, [Figure S6A--E](#sd1){ref-type="supplementary-material"}). Remarkably, p-H3 S10 was almost undetectable in both cell types in CaMKII*δ*-KO mice subjected to 3 weeks of TAC ([Figure 2](#fig02){ref-type="fig"}C, D). Together, these data indicate that CaMKII*δ* regulates H3 phosphorylation in a significant number of differentiated adult ventricular myocytes during cardiac hypertrohy.

Loss of CaMKII*δ* prevents H3 hyperphosphorylation at fetal cardiac genes
-------------------------------------------------------------------------

Cardiac hypertrophy is characterized by transcriptional reprogramming of genes normally expressed during embryonic development, such as *ANP* and *β-MHC*. To investigate whether H3 phosphorylation plays a role in cardiac hypertrophy, we assessed H3 phosphorylation and CaMKII*δ* recruitment at regulatory regions of ANP and *β*-MHC in control and failing human hearts, using chromatin immunoprecipitation (ChIP) followed by qPCR. Increased p-H3 S10 and enhanced recruitment of CaMKII*δ* were observed at both the *ANP* and *β-MHC* promoters in failing hearts compared to control hearts. P-H3 S10 and binding of CaMKII*δ* remained similar at the *α-actin* and *GAPDH* genes, which are not regulated during cardiac hypertrophy ([Figure 3](#fig03){ref-type="fig"}A). Furthermore, CaMKII*δ* expression and p-H3 S10 significantly correlated with ANP and *β*-MHC expression ([Figure 3](#fig03){ref-type="fig"}B; *p* \< 0.05 for each).

![Enhanced p-H3 S10 and CaMKII*δB* recruitment at hypertrophic gene loci in end-stage human heart failure. (A) ChIP assay performed with anti-p-H3 S10 or anti-CaMKII*δ* antibodies, followed by q-PCR, showing increased p-H3 S10 and CaMKII*δ*B recruitment at ANF and *β*-MHC promoters in dilated human hearts compared to control hearts; results are expressed as percentage input over IgG and represent average ± SD (*n =* 3). (B) Correlations between p-H3 S10 or CaMKII*δ* binding and ANP or *β*-MHC expression in normal and failing human hearts; *p* values from Student\'s *t*-test are indicated](path0235-0606-f3){#fig03}

P-H3 S10 progressively increased at the *ANP* and *β-MHC* promoters at 10 days and 3 weeks post-TAC in wild-type mice, which paralleled CaMKII*δ* recruitment. In contrast, this response was blunted in CaMKII*δ*-KO mice subjected to TAC ([Figure 4](#fig04){ref-type="fig"}A, B). P-H3 S10 remained similar at the *α-actin* and *GAPDH* promoters in wild-type and CaMKII*δ*-KO mice after TAC ([Figure 4](#fig04){ref-type="fig"}C, D). These data show that H3 phosphorylation fails to increase in response to pressure overload hypertrophy when CaMKII*δ* is not expressed in the myocardium. Taken together, these data suggest that p-H3 S10 is important for the re-activation of at least two fetal cardiac genes during cardiac hypertrophy.

![Reduced p-H3 S10 and CaMKII*δB* recruitment at hypertrophic gene loci in CaMKII*δ*-KO mice after TAC. ChIP--qPCR performed from heart tissue homogenates, showing (A) p-H3 S10 and (B) CaMKII*δ* binding at the ANP and *β*-MHC promoters in WT or CaMKII*δ*-KO mice, 10 or 21 days after sham operation or TAC. (C, D) qPCR reactions at *GAPDH* and *α-actin* promoters that are not responsive to pressure overload hypertrophy. Results are expressed as percentage input over signals with IgG antibody and represent average ± SD (*n =* 3). *p* values from Student\'s *t*-test are indicated](path0235-0606-f4){#fig04}

Increased binding of 14--3--3 to p-H3 S10 in human failing hearts and enhanced Mef2 transcription in the presence of 14--3--3
-----------------------------------------------------------------------------------------------------------------------------

14--3--3 is a chaperone protein that binds and is recruited to specific inducible promoters when these are transcriptionally active \[[@b28],[@b29]\]. Based on this, we hypothesized that 14--3--3 may bind phosphorylated H3 at fetal cardiac genes upon hypertrophic stimulation. To test this, we first examined 14--3--3 expression in the normal and failing human heart and saw no significant changes in global expression ([Figure 5](#fig05){ref-type="fig"}A). However, increased interaction of 14--3--3 with p-H3 S10 was detected in human failing hearts compared to control hearts ([Figure 5](#fig05){ref-type="fig"}B). A gel-shift assay performed with recombinant nucleosomes and purified CaMKII*δ*B, in the presence or absence of 14--3--3, confirmed that CaMKII*δ* and 14--3--3 form a complex in chromatin (see supplementary material, [Figure S7A](#sd1){ref-type="supplementary-material"}). Binding of 14--3--3 to p-H3 S10 was detected in wild-type mice after 3 weeks of TAC and was reduced in CaMKII*δ*-KO TAC animals ([Figure 5](#fig05){ref-type="fig"}C). Next we over-expressed wild-type or mutant H3 S10A in cells and assessed 14--3--3/H3 interaction by immunoprecipitation, followed by immunoblotting. Decreased binding of 14--3--3 to mutant H3 S10A was observed, indicating that 14--3--3 preferentially binds to p-H3 S10 ([Figure 5](#fig05){ref-type="fig"}D).

![Increased interaction of 14--3--3 with p-H3 S10 after pathological stress and enhanced transcription of Mef2 in the presence of 14--3--3. (A) Immunoblot analysis from control (*n =* 4) and failing human hearts (*n =* 4) showing similar expression of 14--3--3. (B) Immunoprecipitation with anti-p-H3 S10 antibody or control IgG followed by immunoblotting showing increased interaction between 14--3--3 and p-H3 S10 in human dilated hearts. (C) Reduced binding between 14--3--3 and p-H3 S10 in CaMKII*δ*-KO mice, 3 weeks after TAC. (D) Immunoprecipitation performed with anti-Flag antibody, followed by immunoblotting using the indicated antibodies from Cos-7 cells expressing wild-type or mutant Flag-H3S10A, showing reduced binding of 14--3--3 to mutant p-H3 S10A. (E) *In vitro* transcription assay from DNA templates harbouring multimerized Mef2-binding sites and chromatin reconstituted with wild-type H3 or mutant H3 S10A \[[@b25]\] after addition of recombinant CaMKII*δ*B, 14--3--3 and nuclear extracts. CaMKII*δ*B-mediated chromatin transcription requires p-H3 S10 and 14--3--3 enhances the rate of Mef-2 transcription](path0235-0606-f5){#fig05}

Mef2 is a transcription factor present at regulatory regions of many cardiac-specific genes and is a point of convergence of many hypertrophic signalling pathways \[[@b15]\]. We reported that S10 phosphorylation by CaMKII*δ* is required for Mef2 to be transcribed from chromatin templates \[[@b25]\]. Thus, we measured the amount of Mef2 transcribed when chromatin is reconstituted with wild-type H3 or mutant H3 S10A in the presence or absence of 14--3--3; the latter increased the rate of Mef2 transcription with wild-type H3 but not with mutant H3 S10A ([Figure 5](#fig05){ref-type="fig"}E; see also supplementary material, [Figure S7B](#sd1){ref-type="supplementary-material"}). All together, these data show that 14--3--3 binds to p-H3 S10 and that this interaction increases Mef2 transcription from chromatin templates.

14--3--3 binding to chromatin is required for transcriptional elongation of fetal cardiac genes
-----------------------------------------------------------------------------------------------

To establish the functional link between H3 phosphorylation, 14--3--3 recruitment and the transcriptional reprogramming of fetal cardiac genes, we assessed 14--3--3 binding at fetal cardiac genes in CaMKII*δ* wild-type and KO mice subjected to sham operation or TAC. 14--3--3 binding increased significantly at the *ANP* and *β-MHC* promoters and exonic region after stress in wild-type mice, but this effect was significantly reduced in CaMKII*δ*-KO mice ([Figure 6](#fig06){ref-type="fig"}A). Phosphorylation of RNAPII at serine 2 (p-RNAPII S2) is associated with transcription elongation, which requires 14--3--3 \[[@b30]\]. Therefore, we assessed p-RNAPII S2 at the promoter and exonic region of fetal cardiac genes and of GATA-4 in neonatal rat cardiomyocytes transfected with control siRNA (siCT) or siRNA against 14--3--3 (si14--3--3) after stimulation with the hypertrophic agonist phenylephrine ([Figure 6](#fig06){ref-type="fig"}B). As previously reported \[[@b30]\], 14--3--3 knockdown reduced p-RNAPII S2 ([Figure 6](#fig06){ref-type="fig"}B). p-RNAPII S2 was relatively low at the promoters of *ANP*, *β-MHC* and *GATA-4* in both siCtr- and si14--3--3-transfected cells ([Figure 6](#fig06){ref-type="fig"}C). p-RNAPII S2 increased at *ANP*, *β-MHC* and *GATA-4* exonic regions in cells with normal expression of 14--3--3, but not in cells with reduced 14--3--3 levels ([Figure 6](#fig06){ref-type="fig"}C). We also observed increased p-RNAPII S2 at *ANP* and *β-MHC* exonic regions, while it decreased at the promoter region of both genes in wild-type mice subjected to TAC, but not in CaMKII*δ*-KO mice after TAC ([Figure 6](#fig06){ref-type="fig"}D, E). Taken together, these results suggest that 14--3--3 binding to phosphorylated H3 is important for the recruitment of RNAPII and elongation of fetal cardiac genes and *GATA-4* during cardiac hypertrophy.

![14--3--3 recruitment to chromatin is important for transcriptional elongation of *GATA-4* and of fetal cardiac genes. (A) ChIP--qPCR performed from mouse heart tissues showing 14--3--3 binding at the ANP and *β*-MHC promoters in CaMKII*δ*-WT or CaMKII*δ*-KO mice 21 days after sham operation or TAC. qPCR reactions were also performed at *GAPDH* and *α-actin* promoters that are not responsive to pressure overload hypertrophy: results are expressed as percentage input over signals with IgG antibody and represent average ± SD (*n =* 3); *p* values from Student\'s *t* test are indicated. (B) Immunoblotting of cardiomyocytes expressing reduced 14--3--3 (si14--3--3) or normal 14--3--3 (siControl). (C) ChIP--qPCR, showing p-RNAPII S2 at the promoter and internal exon of *ANP*, *β-MHC*, *GATA-4*, *GAPDH* and *actin* in primary neonatal rat cardiomyocytes with siCt or si14--3--3 and stimulated with phenylephrine (PE) for 24 h. (D) ChIP--qPCR assay from mouse heart chromatin, showing p-RNAPII S2 at the *ANP*, *β-MHC*, *actin* and *GAPDH* exonic region in CaMKII*δ*-WT or CaMKII*δ*-KO animals, 21 days after sham operation or TAC. (E) ChIP--qPCR assay, showing p-RNAPII S2 at the *ANP*, *β-MHC*, *actin* and *GAPDH* promoter regions in CaMKII*δ*-WT or CaMKII*δ*-KO animals, 21 days after sham operation or TAC: results are expressed as percentage input over signals with IgG antibody, and represent average ± SD (*n =* 3); *p* values from Student\'s *t*-test are indicated](path0235-0606-f6){#fig06}

Discussion
==========

CaMKII enzyme is central to pathological hypertrophic pathways, structural heart disease, arrhythmia and diabetes \[[@b19]--[@b22],[@b31],[@b32]\]. We recently reported that in isolated cells, CaMKII*δ* interacts with H3 to increase p-H3 S10, and that the S10 site is critical for chromatin-dependent transcription of Mef2 \[[@b25]\]. In the present study, we show that H3 phosphorylation is regulated by CaMKII*δ in vivo*, and that this modification controls fetal cardiac gene expression in response to pressure overload. Mechanistically, fetal cardiac genes are activated by binding of 14--3--3 to phosphorylated H3, which facilitates the transcription elongation by RNAPII ([Figure 7](#fig07){ref-type="fig"}).

![Hypothetical model showing the regulation of H3 phosphorylation by CaMKII*δ* in response to haemodynamic stress. Pressure overload hypertrophy increases CaMKII*δ*, which is subsequently recruited to chromatin regions to phosphorylate H3 at S10. H3 hyperphosphorylation relaxes chromatin, allowing binding of 14--3--3 and recruitment of transcription factors (ie *GATA-4*, *Mef2*) to promote transcriptional elongation of hypertrophic genes by RNAPII](path0235-0606-f7){#fig07}

Our study documents that CaMKII*δ* controls H3 phosphorylation during the development of cardiac hypertrophy in the animal, and that similar changes occur in end-stage human heart failure. Indeed, we observed a robust phosphorylation of H3 in mouse hearts subjected to pressure overload hypertrophy and in human dilated hearts. H3 phosphorylation appears to be an early event coinciding with up-regulation of c-Myc and GATA-4, which are early drivers of cardiac hypertrophy. These changes occur prior to the decline in cardiac function characteristic of cardiac decompensation and heart failure. Strikingly, the increased H3 phosphorylation and expression of proteins driving early hypertrophic signalling in response to pathological stress do not occur in CaMKII*δ*-KO mice. Primary cardiomyocytes expressing mutant H3 S10A that cannot be phosphorylated have reduced size compared to cells expressing wild-type H3. Collectively, these results indicate that CaMKII*δ* regulates H3 phosphorylation in the stressed myocardium and that this modification is critical for cellular hypertrophy.

Our data showing that CaMKII*δ* deletion protects against cardiac hypertrophy and fibrosis are consistent with results of the Olson laboratory \[[@b20]\]. However, another group showed that CaMKII*δ* deficiency protects from dilatation and systolic dysfunction but does not confer antihypertrophic effects \[[@b31]\]. Differences may be due to different gene-targeting strategies; alternatively, the discrepancy may be explained by different surgical procedures or different genetic backgrounds. Thus, it will be interesting to investigate whether loss of H3 phosphorylation occurs in both models of CaMKII*δ* deficiency. While global deletion of CaMKII*δ* protects against heart diseases \[[@b32]\], nuclear CaMKII*δ*B exerts cardioprotective effects by increased transcription of heat-shock genes and increased binding of GATA-4 to the Bcl2 promoter \[[@b33],[@b34]\]. Thus, CaMKII splice variants may have antagonistic roles, due to their different subcellular localizations. Alternatively, CaMKII isoforms may be regulated differently in various models of heart disease. In any case, the broad distribution of CaMKII enzyme in various tissues and its implication in a wide range of pathologies suggest that CaMKII*δ* signalling to H3 is likely to affect a broad range of transcriptional programmes.

H3S10 is a \'classical\' mitotic marker \[[@b8]\]. In heart muscle, H3 phosphorylation occurs in cardiomyocytes during fetal and post-natal life, and in young adults, due to cellular proliferation that still exists at these two developmental stages \[[@b11],[@b12]\]. Recent studies indicate that cardiomyocyte mitosis and proliferation can be induced in the adult myocardium by manipulation of specific pathways \[[@b35]--[@b38]\]. In spite of this, the proliferative capacity of the normal adult myocardium is very low. Increased H3 phosphorylation has been reported in the adult heart after pathological stress \[[@b13],[@b14],[@b39]\]. However, the cellular kinases regulating this modification, and whether it exists in different cells populating the myocardium, remain unclear. Since CaMKII*δ* knockout mice are resistant to pathological cardiac hypertrophy \[[@b20]\], our observation that H3 phosphorylation fails to increase in CaMKII*δ*-KO mice after pressure overload implies that in heart muscle, p-H3 S10 has a function in cellular proliferation but also in cellular hypertrophy. In support of this, H3 phosphorylation is induced not only in non-cardiac cells but also in ventricular myocytes after pressure overload hypertrophy in wild-type mice, but not in CaMKII*δ*-deficient mice. Hypertrophic promoters are hyperphosphorylated after pressure overload, and this response coincides with CaMKII*δ* recruitment at the very same regions, while H3 phosphorylation remains low at promoter regions of hypertrophic genes in CaMKII*δ*-KO mice after haemodynamic stress. Thus, in ventricular myocytes, H3 phosphorylation likely regulates a subset of genes, those implicated in early hypertrophic signalling, such as *c-Myc* and *GATA-4*, and also fetal cardiac genes. Because H3 phosphorylation is totally blunted in CaMKII*δ*-KO mice, our data also suggest that H3 phosphorylation by CaMKII*δ* may regulate cardiac fibroblast proliferation. Future assessment of fibroblast turnover and collagen synthesis should address this possibility. The finding that H3 phosphorylation plays a role in cellular hypertrophy, although initially surprising, is perhaps not so unexpected. Many common mechanisms are shared between the fetal and the diseased heart. For instance, the chromatin remodeller Brg1 regulates cardiomyocyte proliferation in the embryonic heart and hypertrophy in the adult myocardium \[[@b18]\] by assembly of different proteins and chromatin remodellers during cardiac development and in disease. Experiments are ongoing to attempt to identify mega-protein complexes formed in chromatin in response to pathological cardiac stress.

Regarding the switch of MHC isoforms during cardiac hypertrophy, increased expression of *β*-MHC in a small pool of cardiomyocytes located in the base of the heart near large coronary arteries and towards the right ventricle was recently reported to confer resistance to cardiac hypertrophy \[[@b40]\]. Since our human tissue samples were systematically collected from the lower left ventricle, the increase in *β*-MHC in human cardiomyopathic hearts is likely not associated with cardioprotective effects. Assessment of *β*-MHC and *α*-MHC together with phosphorylated H3 in different regions of the murine myocardium should reveal whether *β*-MHC and H3 are co-expressed in the same cell, and mark cardiomyocytes that are resistant or sensitive to pressure overload hypertrophy. In either case, the *in vivo* regulation of H3 phosphorylation by CaMKII*δ* reveals a new function of CaMKII*δ* in chromatin modification.

14--3--3 proteins are scaffolding proteins that interact with chromatin-modifying proteins and with H3 to regulate a variety of processes, such as transcription \[[@b28],[@b29]\]. On this basis, we hypothesized that 14--3--3 may bind to p-H3 S10 in the adult heart as an underlying mechanism for hypertrophic gene activation. Our mouse and human data show increased interaction of 14--3--3 with phosphorylated H3 after pressure overload hypertrophy. Reduced interaction is observed in CaMKII*δ*-deficient mice and in cells where S10 in H3 is mutated. Functionally, interaction of 14--3--3 with p-H3 S10 is important for Mef2-dependent transcription of hypertrophic targets. These results indicate that 14--3--3--H3 interaction specializes in the transcription of hypertrophic genes. To further establish this, we assessed p-RNAPII S2, which is required for RNAPII release from proximal promoters and for transcription elongation \[[@b41]\]. RNAPII S2 level was higher at exonic regions of *ANP*, *β-MHC* and *GATA-4* compared to their promoter region and reducing 14--3--3 decreased RNAPII S2 levels. After pressure overload, p-RNAPII S2 increased at *ANP*, *β-MHC* and *GATA-4* exonic regions in wild-type mice, but not in CaMKII*δ*-KO mice, indicating that productive elongation is impaired in mice deficient for CaMKII*δ*. Thus, 14--3--3 localizes with actively transcribed hypertrophic genes, allowing RNAPII transcription elongation, and this localization is dependent on phosphorylated H3.

CaMKII*δ* regulates cardiac hypertrophy by acetylation of histones. This mechanism occurs after CaMKII*δ* selectively phosphorylates HDAC4, which becomes exported outside the nucleus with other class II HDACs and can no longer repress Mef2 \[[@b23],[@b24]\]. However, the absence of a cardiac phenotype in *HDAC4* knockout mice suggests the possibility of another layer of regulation \[[@b42]\]. Our results suggest that CaMKII*δ* signalling to H3 represents an additional regulatory mechanism. Since the \'histone code\' hypothesis predicts a crosstalk between the various histone markers, and phosphorylation of H3 is known to influence H3 acetylation \[[@b43],[@b44]\], it is likely that both markers co-exist and are implicated in cardiac hypertrophy development. Also, HDAC4 has recently been shown to control H3 methylation during pathological cardiac stress, possibly through a CaMKII*δ*-dependent mechanism \[[@b45]\]. This raises the exciting possibility that H3 phosphorylation may be an early signal regulating H3 acetylation and methylation status. The bigger question, of course, relates to the sequence of these events and how they occur chronologically to alter specific transcriptional programmes.

In summary, our data show that chromatin regulation by CaMKII*δ*-mediated H3 phosphorylation is an important mechanism for fetal cardiac gene activation during cardiac hypertrophy. With the recent development of large-scale epigenetic studies, assessment of H3 phosphorylation and binding of CaMKII*δ* across the genome, using ChIP-seq, should provide a deeper understanding of genome-wide functional consequences of H3 modification by CaMKII*δ*. The future identification of protein complexes formed in chromatin and other H3 post-translational modifications in the normal and diseased myocardium should also help to understand how growth mechanisms are regulated in the normal and diseased heart. This may help identify new points of control at the level of chromatin to develop novel strategies for the treatment of major cardiac diseases.
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